A Phase 2 interventional study of Nivolumab in Head and Neck Cancer, sponsored by Trisha Wise-Draper. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Trisha Wise-Draper · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing nivolumab in Head and Neck Neoplasms — 1 open to participants now, 6 under way, 1 of them phase 3. Nivolumab · Head and Neck Neoplasms.
Among the 18 studies testing nivolumab in Head and Neck Neoplasms, this one is the 6th largest by enrollment, is one of 4 that started in 2017, is one of 10 in phase 2, and was the 8th registered.
2,716 studies on the registry are indexed under Head and Neck Neoplasms; 598 are open to participants now.
Browse Head and Neck Neoplasms studies →1 of the 18 studies testing nivolumab in Head and Neck Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Vanderbilt-Ingram Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, nivolumab is the treatment under test here. Read study by study →
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 3
First in 2016; this study’s year is marked. 4 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 39 is below the median of 46 across 2,034 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 24 across the 18 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 18 have an industry lead sponsor. The 10 most frequent:
Trisha Wise-Draper is the lead sponsor of 5 studies on the registry; none are open to participants now.
Trisha Wise-Draper has 3 studies filed under Head and Neck Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies testing nivolumab in Head and Neck Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05327270M.D. Anderson Cancer CenterNon-randomized, Open-label Study of Intralesional Nivolumab for High Risk Oral Premalignant Lesions | 2027-02-02 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies testing nivolumab in Head and Neck Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to test the safety and efficacy of nivolumab after salvage resection in head and neck cancer in patients that have previously received definitive radiation with or without chemotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nivolumab starting 4-11 weeks after surgery for 6 doses.
Drug: Nivolumab
Nivolumab 480 mg IV infusion
Also known as: Opdivo
Percentage of Patients With Grade 3 and 4 Adverse Events of Nivolumab
As determined by CTCAE v5.0 and Grade 3 or 4 adverse event rate was determined by counting the number of subjects that had at least one Grade 3 or Grade 4 adverse while on treatment of nivolumab.
Time frame: AEs were collected during the treatment period and for a minimum of 30 days following the last dose of study treatment, up to 7 months.
Percentage of Patients With Any Grade Adverse Events of During Treatment of Nivolumab
As determined by CTCAE v5.0 and Grade 3 or 4 adverse event rate was determined by counting the number of subjects that had at least one adverse while on treatment of nivolumab for a minimum of 30 days following the last dose of study treatment. Adverse Events were not collected beyond the 30 days following the last dose.
Time frame: AE collection occurs during the treatment period and for a minimum of 30 days following the last dose of study treatment, up to 7 months.
Disease Free Survival
The primary endpoint of this study was disease free survival (DFS) at 2-years as measured from the time of treatment allocation to the first evidence of any tumor or death from any cause. The "median follow-up of 22.1 months" reflects the actual duration of follow-up across participants at the time of data analysis. While the outcome measure was designed to be assessed at the 2-year mark, not all participants had reached exactly 24 months of follow-up when the data were analyzed. Therefore, the median follow-up time represents the central tendency of the follow-up duration for the cohort.
Time frame: Median follow up was 22.1 months
Disease Free Survival
Time frame: 2 year
| Milestone | Nivolumab |
|---|---|
| Started | 39 |
| Completed | 39 |
| Not completed | 0 |
As determined by CTCAE v5.0 and Grade 3 or 4 adverse event rate was determined by counting the number of subjects that had at least one Grade 3 or Grade 4 adverse while on treatment of nivolumab.
| Participants | Nivolumab |
|---|---|
| Percentage of Patients With Grade 3 and 4 Adverse Events of Nivolumab | 17 |
As determined by CTCAE v5.0 and Grade 3 or 4 adverse event rate was determined by counting the number of subjects that had at least one adverse while on treatment of nivolumab for a minimum of 30 days following the last dose of study treatment. Adverse Events were not collected beyond the 30 days following the last dose.
| Participants | Nivolumab |
|---|---|
| Percentage of Patients With Any Grade Adverse Events of During Treatment of Nivolumab | 37 |
The primary endpoint of this study was disease free survival (DFS) at 2-years as measured from the time of treatment allocation to the first evidence of any tumor or death from any cause. The "median follow-up of 22.1 months" reflects the actual duration of follow-up across participants at the time of data analysis. While the outcome measure was designed to be assessed at the 2-year mark, not all participants had reached exactly 24 months of follow-up when the data were analyzed. Therefore, the median follow-up time represents the central tendency of the follow-up duration for the cohort.
| percentage of participants | Nivolumab |
|---|---|
| Disease Free Survival | 71.4 (57.8 to 88.1) |
| Percentage of subjects | Nivolumab |
|---|---|
| Disease Free Survival | 71.37 (57.8 to 88.8) |
Collected over AEs were collected during the treatment period and for a minimum of 30 days following the last dose of study treatment, up to 7 months.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nivolumab | 10/39 (25.6%) | 9/39 (23.1%) | 37/39 (94.9%) |
| Event | Nivolumab |
|---|---|
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/39 |
| Abdominal wall cellulitisInfections and infestations | 1/39 |
| Acute kidney injuryRenal and urinary disorders | 1/39 |
| AspirationRespiratory, thoracic and mediastinal disorders | 1/39 |
| Bone infectionInfections and infestations | 1/39 |
| Cardiac arrestCardiac disorders | 1/39 |
| EncephalopathyNervous system disorders | 1/39 |
| HypotensionVascular disorders | 1/39 |
| Malignant Neoplasm ProgressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/39 |
| Peripheral sensory neuropathyNervous system disorders | 1/39 |
| Event | Nivolumab |
|---|---|
| FatigueGeneral disorders | 14/39 |
| Weight lossInvestigations | 9/39 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/39 |
| DiarrheaGastrointestinal disorders | 7/39 |
| Weight gainInvestigations | 7/39 |
| AnorexiaMetabolism and nutrition disorders | 6/39 |
| DysphagiaGastrointestinal disorders | 6/39 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 6/39 |
| PainGeneral disorders | 6/39 |
| ParesthesiaNervous system disorders | 6/39 |
39 subjects that received at least one dose of Nivolumab
| Age, Continuous(years) | Nivolumab |
|---|---|
| Median | 68 (49 to 85) |
| Sex: Female, Male(Participants) | Nivolumab |
|---|---|
| Female | 12 |
| Male | 27 |
| Ethnicity (NIH/OMB)(Participants) | Nivolumab |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 39 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Nivolumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 34 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Nivolumab |
|---|---|
| United States | 39 |
| >10 pack year tobacco smoking history(Participants) | Nivolumab |
|---|---|
| Count of participants | 24 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2017 to primary completion in Jan 2024, 72 months.
Results were first posted in May 2026, 2 years 4 months after primary completion.
Of 216 non-industry phase 2 interventional studies under Head and Neck Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 84. This study's 72 months is above that.
Counting every sponsor, half of 260 studies reached it within 51 months; a quarter within 30 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab
Trisha Wise-Draper